Laverock Therapeutics has secured over £2.2 million in grants to advance its innovative single-cell and AI-driven gene-control platform. The funding will enhance the development of treatments in solid tumors and expand their applications into non-oncology therapeutic areas. The first project focuses on scaling the T-cell platform using patient data to optimize cancer treatment options, while the second grant aims to innovate macrophage-based therapies. CEO David Venables highlighted that this validation will boost their product development efforts as they move closer to clinical applications.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/press-releases/laverock-therapeutics-awarded-in-excess-of-2-2m-through-two-innovation-grants-to-support-ai-powered-platform-development-and-to-expand-therapeutic-programmes-outside-of-oncology
